Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe AsthmaGlobeNewsWire • 02/11/26
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe AsthmaGlobeNewsWire • 02/10/26
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP StudySeeking Alpha • 12/05/25
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued ProgressGlobeNewsWire • 11/05/25
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society CongressGlobeNewsWire • 09/30/25
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumGlobeNewsWire • 09/09/25
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)GlobeNewsWire • 09/02/25
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)GlobeNewsWire • 09/01/25
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued ProgressGlobeNewsWire • 08/06/25
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)GlobeNewsWire • 07/08/25
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorGlobeNewsWire • 06/15/25
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025GlobeNewsWire • 06/05/25
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/25
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical ProgramsGlobeNewsWire • 05/06/25
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/12/25
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting DifferentiationSeeking Alpha • 12/16/24